News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 14, 2019
FARMINGDALE, N.Y., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 12, 2019Total revenues of $5.7 million for the second quarter 2019 compared to $6.8 million for the second quarter 2018.
Dallas, TX, August 12, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2019 financial...
- Aug 12, 2019
FARMINGDALE, N.Y., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 08, 2019Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN for BPH and NDA Submission Expected in Summer 2020 Company to Host Investor Conference Call on Thursday, August 8, 2019, 8 a.m. ET
MIAMI, Aug. 08, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 08, 2019--Webcast and conference call today at 4:30 p.m. ET --
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 08, 2019Second Quarter Gross Margin Increased Almost 370 Basis Points Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.7 million for the second quarter ended June 30, 2019, a decrease of 29% compared to the second...
- Aug 07, 2019
FARMINGDALE, N.Y., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 07, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period...
- Aug 06, 2019ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019
DEER PARK, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 06, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 05, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2019 financial and operating results on Thursday, August 8, 2019 after the...
- Aug 02, 2019U.S. market not affected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO® lots released in the Canadian and South...
- Aug 01, 2019
MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 01, 2019-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020
DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 01, 2019Final study results accepted for “Late Breaking Presentation” on October 16, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO® Spermatogenesis Study results have been accepted for presentation as a...
- Jul 30, 2019
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 30, 2019Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The...
- Jul 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the...
- Jul 24, 2019NATESTO® Now Covered on Payer Plans Covering Over 6 Million U.S. Lives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO® (testosterone nasal gel) is now on formulary...
- Jul 19, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated...
- Jul 18, 2019
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jul 18, 2019
FARMINGDALE, N.Y., July 18, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jul 12, 2019
DEER PARK, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 11, 2019Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community
BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders...